Santiago Ferrer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5588988/publications.pdf

Version: 2024-02-01

63 papers	4,071 citations	147566 31 h-index	118652 62 g-index
69 all docs	69 docs citations	69 times ranked	4743 citing authors

#	Article	IF	Citations
1	Chemical genetics of Plasmodium falciparum. Nature, 2010, 465, 311-315.	13.7	515
2	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	13.7	353
3	Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential. Journal of Medicinal Chemistry, 2011, 54, 5540-5561.	2.9	255
4	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science Translational Medicine, 2015, 7, 296ra111.	5.8	254
5	Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Science Translational Medicine, 2017, 9, .	5.8	204
6	(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5455-62.	3.3	199
7	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Science Translational Medicine, 2013, 5, 177ra37.	5.8	187
8	A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes. PLoS ONE, 2008, 3, e2252.	1.1	139
9	Genetic analysis of the chitinase system of Serratia marcescens 2170. Journal of Bacteriology, 1997, 179, 7111-7117.	1.0	134
10	A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission. Nature Communications, 2017, 8, 430.	5.8	110
11	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nature Communications, 2014, 5, 5521.	5.8	108
12	Falcipain Inhibitors: Optimization Studies of the 2-Pyrimidinecarbonitrile Lead Series. Journal of Medicinal Chemistry, 2010, 53, 6129-6152.	2.9	102
13	Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia. Journal of Infectious Diseases, 2015, 211, S96-S106.	1.9	93
14	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infectious Diseases, 2016, 2, 945-957.	1.8	71
15	Repurposing clinically approved cephalosporins for tuberculosis therapy. Scientific Reports, 2016, 6, 34293.	1.6	66
16	High seroprevalence of Pneumocystis infection in Spanish children. Clinical Microbiology and Infection, 2004, 10, 1029-1031.	2.8	63
17	Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. EBioMedicine, 2016, 8, 291-301.	2.7	60
18	Polyphasic Taxonomy of a Novel Yeast Isolated from Antarctic Environment; Description of Cryptococcus victoriae sp. nov.. Systematic and Applied Microbiology, 1999, 22, 97-105.	1.2	58

#	Article	IF	Citations
19	Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1. Future Medicinal Chemistry, 2012, 4, 2311-2323.	1.1	56
20	Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. Journal of Medicinal Chemistry, 2016, 59, 9890-9905.	2.9	51
21	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	5.8	51
22	Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity. Journal of Medicinal Chemistry, 2016, 59, 5416-5431.	2.9	50
23	Preclinical Drug Metabolism and Pharmacokinetic Evaluation of GW844520, A Novel Anti-Malarial Mitochondrial Electron Transport Inhibitor. Journal of Pharmaceutical Sciences, 2006, 95, 2657-2672.	1.6	49
24	Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans. Antimicrobial Agents and Chemotherapy, 2015, 59, 950-959.	1.4	43
25	Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents. European Journal of Medicinal Chemistry, 2012, 49, 365-378.	2.6	41
26	Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development. Antimicrobial Agents and Chemotherapy, 2016, 60, 3669-3675.	1.4	40
27	N-Aryl-2-aminobenzimidazoles: Novel, Efficacious, Antimalarial Lead Compounds. Journal of Medicinal Chemistry, 2014, 57, 6642-6652.	2.9	37
28	Potent antimalarial 4-pyridones with improved physico-chemical properties. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5214-5218.	1.0	36
29	Repositioning: the fast track to new anti-malarial medicines?. Malaria Journal, 2014, 13, 143.	0.8	36
30	Bacteriocin 28b, a chromosomally encoded bacteriocin produced by most Serratia marcescens biotypes. Research in Microbiology, 1995, 146, 477-483.	1.0	35
31	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Doseâ€“Efficacy Modeling. PLoS Medicine, 2016, 13, e1002138.	3.9	35
32	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	2.9	33
33	Genetic evidence for an activator required for induction of colicin-like bacteriocin 28b production in Serratia marcescens by DNA-damaging agents. Journal of Bacteriology, 1996, 178, 951-960.	1.0	32
34	A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum -Infected Mouse Models from Structureâ€“Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines. Journal of Medicinal Chemistry, 2015, 58, 8713-8722.	2.9	32
35	Cyclopropyl Carboxamides, a Chemically Novel Class of Antimalarial Agents Identified in a Phenotypic Screen. Antimicrobial Agents and Chemotherapy, 2011, 55, 5740-5745.	1.4	30
36	Aminoindoles, a Novel Scaffold with Potent Activity against Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2011, 55, 2612-2622.	1.4	29

#	Article	IF	Citations
37	Cloning and DNA sequence analysis of a bacteriocin gene of Serratia marcescens. Journal of General Microbiology, 1992, 138, 1737-1743.	2.3	26
38	A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery. PLoS ONE, 2013, 8, e66967.	1.1	26
39	Cloning and characterization of two Serratia marcescens genes involved in core lipopolysaccharide biosynthesis. Journal of Bacteriology, 1996, 178, 5741-5747.	1.0	24
40	Antifungal Activities of Two New Azasordarins, GW471552 and GW471558, in Experimental Models of Oral and Vulvovaginal Candidiasis in Immunosuppressed Rats. Antimicrobial Agents and Chemotherapy, 2001, 45, 3304-3309.	1.4	24
41	Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents. Journal of Medicinal Chemistry, 2014, 57, 5702-5713.	2.9	24
42	Molecular characterization of a 17-kDa outer-membrane protein from Klebsiella pneumoniae. Research in Microbiology, 1997, 148, 133-143.	1.0	23
43	Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. Journal of Medicinal Chemistry, 2020, 63, 4929-4956.	2.9	23
44	Bacteriocin 28b fromSerratia marcescensN28b: identification ofEscherichia colisurface components involved in bacteriocin binding and translocation. Canadian Journal of Microbiology, 1996, 42, 19-26.	0.8	21
45	The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 133-141.	0.8	21
46	Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rî³^{null} Mouse Model of Malaria. Journal of Medicinal Chemistry, 2018, 61, 4213-4227.	2.9	19
47	4â€Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tweenâ€80 inâ€...vitro Dependent Families of Antitubercular Agents with Moderate inâ€...vivo Activity. ChemMedChem, 2011, 6, 2252-2263.	1.6	17
48	Synthesis and Structureâ€“Activity Relationships of the Novel Antimalarials 5-Pyridinyl-4(1H)-Pyridones. Journal of Medicinal Chemistry, 2018, 61, 3422-3435.	2.9	15
49	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	2.9	13
50	A 17 kDa outer-membrane protein (Omp4) from Serratia marcescens confers partial resistance to bacteriocin 28b when expressed in Escherichia coli. Microbiology (United Kingdom), 1995, 141, 2535-2542.	0.7	11
51	The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold. Journal of Medicinal Chemistry, 2017, 60, 6880-6896.	2.9	11
52	Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria. Bioorganic and Medicinal Chemistry, 2018, 26, 2996-3005.	1.4	11
53	Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives. ACS Medicinal Chemistry Letters, 2014, 5, 657-661.	1.3	10
54	Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. European Journal of Pharmaceutical Sciences, 2016, 93, 319-333.	1.9	9

#	Article	IF	Citations
55	A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers. British Journal of Clinical Pharmacology, 2018, 84, 482-489.	1.1	9
56	Seroprevalence of Pneumocystis Human Infection in Southern Spain. Journal of Eukaryotic Microbiology, 2003, 50, 649-650.	0.8	7
57	Protection against bacteriocin 28b in Serratia matcescens is apparently not related to the expression of an immunity gene. Canadian Journal of Microbiology, 1995, 41, 217-226.	0.8	6
58	Humanised models of infection in the evaluation of anti-malarial drugs. Drug Discovery Today: Technologies, 2013, 10, e351-e357.	4.0	6
59	Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones. Journal of Computer-Aided Molecular Design, 2020, 34, 1117-1132.	1.3	6
60	A novel class of fastâ€acting antimalarial agents: Substituted 15â€membered azalides. British Journal of Pharmacology, 2021, 178, 363-377.	2.7	5
61	Antibacterial Activities and Pharmacokinetics of E-4767 and E-5065, Two New 8-Chlorofluoroquinolones with a 7-Azetidin Ring Substituent. Antimicrobial Agents and Chemotherapy, 2001, 45, 3113-3121.	1.4	4
62	Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis. PLoS Neglected Tropical Diseases, 2021, 15, e0009013.	1.3	4
63	Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection. European Journal of Pharmaceutical Sciences, 2022, 173, 106163.	1.9	2